Earticle

초록

영어

The induced pluripotent stem cell (iPSC) technology pioneered by Yamanaka and his colleagues in 2006 has ignited an explosion of scientific and public interest because these cells can potentially offer an ideal cell source to study and treat numerous human diseases by providing patient- and disease-specific cells. However, widely established methods to generate iPSCs require the use of viral and/or genetic materials that likely integrate into the chromosomal DNAs with unknown genetic changes. Indeed, recent evidence demonstrated that viral-based iPS cells compromise genomic integrity and exhibit abnormal phenotypes. Thus, to realize the therapeutic and biomedical potentials of iPSCs, it is critical to develop reprogramming methods that can avoid or minimize these potential abnormalities. As a potential approach, we attempted to generate iPSCs without the use of viruses or DNA transfection by directly delivering four reprogramming proteins (Oct4, Sox2, Klf4, and c-Myc) fused with a cell penetrating peptide. We also characterized these protein-based iPSCs along with virus-based iPSCs for their molecular and differentiation properties. This presentation will discuss current limitations as well as the potential of protein-based iPSC reprogramming with the long-term goal to use them for eventual personalized medicine.

저자

• Kwang-Soo KIM [ Molecular Neurobiology Laboratory, Program in Neuroscience and Harvard Stem Cell Institute, McLean Hospital/Harvard Medical School. ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국생물공학회 학술대회

• 간기

  반년간

• 수록기간

  1985~2013

• 십진분류

  KDC 476 DDC 576